Similarly, the Prime II trial study found that for women aged ≥65 years or older with early hormone receptor‐positive, node‐ negative BC after breast‐conserving surgery, adjuvant endocrine treatment alone can be a reasonable therapeutic treatment for some women. The gene discussed is NR4A1; the disease is breast cancer.